FindTrial
Sign In

PD:24

8 trials

Sponsors

GlaxoSmithKline Biologicals

Conditions

Booster vaccination against Streptococcus pneumoniae in children 12 to 18 months old.Booster vaccination against Streptococcus pneumoniae in healthy children having previously received vaccines as a primary 3-dose vaccination course in the study 11PN-PD-DIT-002.Booster vaccination against Streptococcus pneumoniae of healthy preterm born children between 16-18 months of age who were previously primed with three doses of GSK Biologicals’10-valent conjugate pneumococcal vaccine co-administered with DTPa-HBV-IPV/Hib in the primary vaccination study 10PN-PD-DIT-015.Booster vaccination against Streptococcus pneumoniae or Haemophilus influenzae in healthy infants 12 to 18 months of age who were previously primed with three doses of pneumococcal conjugate vaccine in the primary vaccination study 10PN-PD-DIT-012 (107007).Booster vaccination against Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b in healthy infants 11 to18 months of age who were previously primed with three doses of pneumococcal conjugate vaccine co-administered with three doses of DTPa-combined and MenC or Hib-MenC vaccines.Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.Three dose vaccination of healthy infants between 8-16 weeks of age at the time of the first vaccination against Streptococcus pneumoniae.Two doses vaccination in elderly subjects aged between 65 and 85 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine (Pneumo 23).

Phase 3

A phase IIIb, observer-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when given as a booster dose between 12-18 months of age in children previously vaccinated in the primary study 10PN-PD-DIT-012 (107007) with either GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar. - 10PN-PD-DIT-018 BST:012
EUCTR2006-005891-41-PL
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae or Haemophilus influenzae in healthy infants 12 to 18 months of age who were previously primed with three doses of pneumococcal conjugate vaccine in the primary vaccination study 10PN-PD-DIT-012 (107007).
Target: 806Updated: 2017-10-02

Unknown Phase

A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488). - 10PN-PD-DIT-004
Active, not recruitingEUCTR2005-003052-36-DE
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae in healthy children having previously received vaccines as a primary 3-dose vaccination course in the study 11PN-PD-DIT-002.
Start: 2005-11-18Target: 689Updated: 2012-03-19
A phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age. - 10PN-PD-DIT-003
Active, not recruitingEUCTR2005-003299-40-DE
GlaxoSmithKline BiologicalsThree dose vaccination of healthy infants between 8-16 weeks of age at the time of the first vaccination against Streptococcus pneumoniae.
Start: 2005-10-18Target: 120Updated: 2012-03-19
A phase I/II, randomized, observer blinded study to evaluate and compare the safety, reactogenicity and immunogenicity of various formulations of the GlaxoSmithKline Biologicals’ adjuvanted 11-valent pneumococcal conjugate vaccine versus the licensed single-dose 23-valent pneumococcal polysaccharide vaccine and GlaxoSmithKline Biologicals’ aluminium-based 10-valent pneumococcal conjugate vaccine, in healthy elderly subjects. - STREP-ELD-010, STREP-ELD-011 EXT010 Y1
Active, not recruitingEUCTR2005-005682-11-SE
GlaxoSmithKline BiologicalsTwo doses vaccination in elderly subjects aged between 65 and 85 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine (Pneumo 23).
Start: 2006-04-24Target: 330Updated: 2012-03-19
A phase IIIb randomised, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-combined, MenC and Hib-MenC vaccines in children as a 3-dose primary immunization course during the first 6 months of age. - 10PN-PD-DIT-011
Active, not recruitingEUCTR2006-000558-30-DE
GlaxoSmithKline BiologicalsThree dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
Start: 2006-06-20Target: 1440Updated: 2012-03-19
A phase IIIa single-blind, controlled multicentre study to assess the safety, reactogenicity and immunogenicity of GSK Biologicals 10-valent pneumococcal conjugate vaccine or Prevenar when given as a fourth dose between 12-18 months of age in children previously vaccinated in infancy in the primary study 10PN-PD-DIT-001 (105553) with either GSK Biologicals 10-valent pneumococcal conjugate vaccine or Prevenar. - 10PN-PD-DIT-007 BST: 001
Active, not recruitingEUCTR2006-001628-38-FI
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae in children 12 to 18 months old.
Start: 2006-07-26Target: 1200Updated: 2012-03-19
A phase III, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when given as a booster dose between 11-18 months of age in children previously vaccinated in the primary study 10PN-PD-DIT-011 (107005) with either GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar. - 10PN-PD-DIT-017 BST 011
Active, not recruitingEUCTR2006-005733-38-DE
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type b in healthy infants 11 to18 months of age who were previously primed with three doses of pneumococcal conjugate vaccine co-administered with three doses of DTPa-combined and MenC or Hib-MenC vaccines.
Start: 2007-04-13Target: 800Updated: 2012-06-12
A phase III open study to assess the safety, reactogenicity and immunogenicity following booster administration of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine, co-administered with a booster dose of DTPa-IPV/Hib (Infanrix-IPV/Hib) vaccine in preterm born children at 16-18 months of age following primary immunisation in study 10PN-PD-DIT-015 (107737) - 10PN-PD-DIT-016 BST:015
Active, not recruitingEUCTR2007-000596-42-GR
GlaxoSmithKline BiologicalsBooster vaccination against Streptococcus pneumoniae of healthy preterm born children between 16-18 months of age who were previously primed with three doses of GSK Biologicals’10-valent conjugate pneumococcal vaccine co-administered with DTPa-HBV-IPV/Hib in the primary vaccination study 10PN-PD-DIT-015.
Start: 2007-10-30Target: 300Updated: 2012-03-19